CVS Health Rallies on Transformative Retail Pharmacy Strategy
CVS Health is transforming its retail pharmacies into comprehensive health hubs, focusing on preventive care and expanding its diverse product offerings.
Healthcare sector stocks including pharmaceuticals, biotechnology, and medical devices.
61 articlesCVS Health is transforming its retail pharmacies into comprehensive health hubs, focusing on preventive care and expanding its diverse product offerings.
A significant $2.93 billion investment from JPMorgan Chase into Eli Lilly (LLY) demonstrates strong confidence in its future growth potential.
Stryker Corp. (SYK) is poised to leverage the booming clinical communication market, projected to hit $5.31 billion by 2030.
SYK's latest quarterly results topped expectations, showcasing impressive growth in key segments. Analysts are optimistic about Stryker Corp.'s future trajectory.
Intellia Therapeutics (NTLA) sees a surge in analyst confidence as H.C. Wainwright raises its price target to $25, spurring investor interest.
HALO makes headlines with its substantial $1.3 billion investment in three biotech acquisitions, reshaping its market position. Find out more.
ELV’s low volatility may seem stable, but it raises questions about long-term performance. How does Elevance Health balance risk and reward?
GSK's fourth-quarter earnings beat expectations with strong revenue and EPS, making it a stock to watch in today's market.
GEHC's recent launches of ReadyFix and Allia Moveo highlight its growth strategy, stirring investor interest and market reactions.
GEHC shares are set to benefit as the company announces a $0.035 cash dividend for Q1 2026, enhancing investor confidence.
Bank of America has revised its price target for Alnylam Pharmaceuticals to $462. What does this mean for ALNY investors?
Ultragenyx Pharmaceutical (RARE) is in the spotlight following robust data on its gene therapy UX111, signaling significant progress for Sanfilippo syndrome.
Recursion Pharmaceuticals (RXRX) has experienced a 57.9% stock decline over the past year, raising valuation concerns. What does this mean for investors?
WAT investors may be surprised by Becton Dickinson's spin-off and Waters Corp.'s $2 billion accelerated share buyback program. What’s next?
RARE reports a 20% revenue increase in 2025 and outlines its strategy for achieving profitability by 2027. Explore the details in this analysis.
RARE shares surged despite posting a wider-than-expected Q4 loss. The strategic restructuring plan aims for profitability by 2027.
LLY experiences a surge as legal concerns mount around competitor Hims offering a low-cost version of a competing product. Find out more.
LLY faces a significant shift as two board members exit. This analysis explores the implications for Eli Lilly shareholders.